<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00235144</url>
  </required_header>
  <id_info>
    <org_study_id>EC00-07</org_study_id>
    <nct_id>NCT00235144</nct_id>
  </id_info>
  <brief_title>The Study of the BX VELOCITY Stent In Patients With De Novo Coronary Artery Lesions.</brief_title>
  <acronym>E-SIRIUS</acronym>
  <official_title>E-Sirius Study: a European, Multi-Center, Randomized, Double-Blind Study of the Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in the Treatment of Patients With de Novo Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the safety and effectiveness of the
      sirolimus-coated Bx VELOCITY™ stent in maintaining minimum lumen diameter in de novo native
      coronary artery lesions as compared to the uncoated Bx VELOCITY balloon-expandable stent.
      Both stents are mounted on the Raptor® Rapid Exchange Stent Delivery System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter (up to 35 centers), prospective, randomized double blind study. This
      study has a 2-arm design assessing the safety and effectiveness of the sirolimus-coated Bx
      VELOCITY stent to the uncoated Bx VELOCITY stent, both mounted on the Raptor Rapid Exchange
      Stent Delivery System. A total of 350 patients will be entered in the study and will be
      randomized on a 1:1 basis. Patients will be either randomized to the sirolimus coated or
      uncoated BX-VELOCITY stent. Patients will be followed at 30 days, 6, 9, and 12 months, and at
      2, 3, 4, 5, 6, 7, and 8 years post-procedure, with all patients undergoing repeat angiography
      at 8 months. Medical resource use during the 5 years follow-up period will be collected and
      analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">October 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent minimum lumen diameter (MLD).</measure>
    <time_frame>8 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of MACE defined as death, myocardial infarction (Q wave and non-Q wave), emergent bypass surgery, or repeat TLR.</measure>
    <time_frame>1, 6, 9, and 12 months; 2, 3, 4, 5, 6, 7 and 8 years post procedure.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic binary restenosis (&gt;=50% diameter stenosis).</measure>
    <time_frame>8 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-lesion MLD.</measure>
    <time_frame>8 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization.</measure>
    <time_frame>9 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization.</measure>
    <time_frame>9 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure defined as cardiac death, myocardial infarction, or target vessel revascularization.</measure>
    <time_frame>9 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success (final residual diameter stenosis of &lt; 50%).</measure>
    <time_frame>any time post-procedure.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">353</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bare-metal stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sirolimus-coated Bx Velocity stent</intervention_name>
    <description>drug-eluting stent</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>uncoated Bx Velocity stent</intervention_name>
    <description>bare-metal stent</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society
             Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald
             Classification B&amp;C, I-II) OR patients with documented silent ischemia;

          2. Treatment of a single de novo native coronary artery lesion in a major coronary artery
             in patients with single or multi-vessel disease; patients with multiple lesions can be
             included only if the other lesions do not require treatment;

          3. Target vessel diameter at the lesion site is &gt;=2.50mm and &lt;=3.0mm in diameter (visual
             estimate);

          4. Target lesion is &gt;=15mm and &lt;=32mm in length (visual estimate);

          5. Target lesion stenosis is &gt;50% and &lt;100% (visual estimate);

        Exclusion Criteria:

          1. Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented
             total CK &gt;2 times normal within the preceding 24 hours and the CK and CK-MB enzymes
             remains above normal at the time of treatment;

          2. Has unstable angina classified as Braunwald III B or C and A I-II-III, or is having a
             peri infarction;

          3. Unprotected left main coronary disease with &gt;=50% stenosis;

          4. Significant (&gt;50%) stenoses proximal or distal to the target lesion that might require
             revascularization or impede runoff;

          5. Have an ostial target lesion;

          6. Angiographic evidence of thrombus within target lesion;

          7. Heavily calcified lesion and/or calcified lesion which cannot be successfully
             predilated;

          8. Documented left ventricular ejection fraction &lt;=25%;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Schofer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzkatheterlabor und Praxisklinik, Hamburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Günter Breithardt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Med. Klinik und Poliklinik, Münster</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herzkatheterlabor und Praxisklinik</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Klinik und Poliklinik</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Hoffmann R, Morice MC, Moses JW, Fitzgerald PJ, Mauri L, Breithardt G, Schofer J, Serruys PW, Stoll HP, Leon MB. Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials. Heart. 2008 Mar;94(3):322-8. Epub 2007 Aug 29.</citation>
    <PMID>17761505</PMID>
  </reference>
  <results_reference>
    <citation>Schampaert E, Moses JW, Schofer J, Schlüter M, Gershlick AH, Cohen EA, Palisaitis DA, Breithardt G, Donohoe DJ, Wang H, Popma JJ, Kuntz RE, Leon MB; SIRIUS, E- and C-SIRIUS Investigators. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol. 2006 Jul 1;98(1):36-41. Epub 2006 May 4.</citation>
    <PMID>16784917</PMID>
  </results_reference>
  <results_reference>
    <citation>Schlüter M, Schofer J, Gershlick AH, Schampaert E, Wijns W, Breithardt G; E- and C-SIRIUS Investigators. Direct stenting of native de novo coronary artery lesions with the sirolimus-eluting stent: a post hoc subanalysis of the pooled E- and C-SIRIUS trials. J Am Coll Cardiol. 2005 Jan 4;45(1):10-3.</citation>
    <PMID>15629365</PMID>
  </results_reference>
  <results_reference>
    <citation>Schofer J, Schlüter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G; E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003 Oct 4;362(9390):1093-9.</citation>
    <PMID>14550694</PMID>
  </results_reference>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2005</study_first_posted>
  <last_update_submitted>May 8, 2009</last_update_submitted>
  <last_update_submitted_qc>May 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Hans-Peter Stoll</name_title>
    <organization>Cordis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

